Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC) are two of the most common vaginal infections affecting women globally, with over 500 million cases each year. These infections not only cause significant discomfort and reduce quality of life, but also contribute to serious health outcomes like 5.4 million preterm births annually and generate healthcare costs exceeding €3.8 billion in Europe alone.
Current treatments often rely on antibiotics and antifungal drugs, which are not always effective and contribute to the global problem of antimicrobial resistance. Gedea aims to change this with the development of pHyph—a patented, antimicrobial-free vaginal tablet that offers a new way to treat and prevent both BV and VVC without requiring lab testing to identify the specific infection. Due to its safety profile, pHyph will be available as an over-the-counter (OTC) product in pharmacies and drugstores, where most women seek help for these conditions.
The innovation lies in pHyph’s dual-action, antimicrobial-free formula and its potential to significantly reduce the use of antibiotics. The product will be brought to market using a scalable business model through partnerships with distributors and pharmaceutical companies across Europe and beyond.
Gedea’s core team brings together over 250 years of combined experience in clinical research, chemistry, regulatory affairs, marketing, and business development. The company has received recognition for its innovation, including the “Rapidus Company of the Year” award and a feature in Labiotech’s “20 European Biotech Companies to Watch.”
During the project, Gedea carries out clinical trials, obtains CE-mark certification, establishes commercial partnerships, and prepares for the product’s market launch in 2026.
